A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

计划入组 60 人 · 首次发布于 2018 年 1 月 31 日

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

计划入组 20 人 · 首次发布于 2015 年 5 月 25 日

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

计划入组 221 人 · 首次发布于 2015 年 6 月 22 日

anticancer agents

hypoglycemic agents

vascular agents

Ethos Technologies

United States

BeyondSpring

United States

Novo Nordisk AS

Sweden

Fitusiran Demonstrates Efficacy in Hemophilia A and B with Reduced Factor Consumption

Real-World Data Supports rpFVIII Use in Acquired Hemophilia A Treatment

Systematic Review Reveals Emicizumab Cost-Effectiveness Varies by Patient Population and Comparator in Hemophilia A Treatment